Clinical trials: RCC
Kidney Neoplasms
MRI Functional Imaging Characteristics and Fat Quantification of CT-fat-free Renal Neoplasms: Relationships With Histological Classifications and Molecular Markers
The knowledge of the histological diagnosis and its subtype of a renal parenchymal tumor is important for determine whether the choice of a specific regimen of chemotherapy, target therapy and immunotherapy could be suitable and…
- Trial name
- NCT06126159
- Testing
- multiparametric and fat-detection magnetic resonance imaging (MRI)
- Where
- Taiwan
- Volunteers
- 44 people
- Sponsor
- Chang Gung Memorial Hospital
Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma
68Ga- and 18F-CAIX PET Imaging Study
This exploratory clinical imaging study will evaluate the safety, tolerability, biodistribution, lesion detection, and tumor uptake characteristics of 68Ga- and 18F-labeled carbonic anhydrase IX (CAIX)-targeted positron emission…
- Conditions
- Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma, Renal Tumor
- Trial name
- CAIX-PET (NCT07875946)
- Testing
- 68Ga-CAIX PET/CT, 18F-CAIX
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Peking University First Hospital
Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma
Study of Adaptive Immunotherapy With VEGFR-TKI in Patients With Advanced RCC
This is a Phase II Clinical Trial that will evaluate the use of adaptive dosing of pembro-axi in patients with Metastatic Clear Cell Renal Cell Carcinoma (mccRCC).
- Trial name
- NCT06860386
- Testing
- Pembrolizumab, Axitinib
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Advanced Renal Cell Carcinoma, Advanced Mesothelioma
Study of CAR.70-engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Advanced Renal Cell Carcinoma, Mesothelioma and Osteosarcoma
To find a recommended dose of donated NK cells that can be given with lymphodepleting chemotherapy to patients with advanced renal cell carcinoma, mesothelioma, or osteosarcoma. The effects of this therapy will also be studied.
- Conditions
- Advanced Renal Cell Carcinoma, Advanced Mesothelioma, Advanced Osteosarcoma
- Trial name
- NCT05703854
- Testing
- CAR.70/IL15-transduced CB-derived NK cells, Fludarabine phosphate, Cyclophosphamide
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- M.D. Anderson Cancer Center
Renal Cell Carcinoma, Kidney Neoplasm
Treatment of Patients With Advanced Renal Cancer With a Radiolabeled Antibody, Yttrium-90 Conjugated Chimeric G250
This was a Phase 1, open-label, dose-escalation study of yttrium-90 conjugated chimeric G250 (^90Y-DOTA-cG250) in patients with advanced, measurable clear cell renal cell carcinoma (RCC).
- Conditions
- Renal Cell Carcinoma, Kidney Neoplasm, Renal Cancer, Kidney Cancer
- Trial name
- NCT00199875
- Testing
- Yttrium-90 conjugated chimeric G250 (^90Y-DOTA-cG250)
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Ludwig Institute for Cancer Research
Genito Urinary Cancer, Bladder Cancer
Reconstitution of a Human Immune System in a Patient Derived Xenograft (PDX) Model of Genitourinary (GU) Cancers
The objective of this study is to obtain human blood CD34+ hematopoietic stem/progenitor cells (HSPCs) to reconstitute a match human immune system in our PDX model.
- Conditions
- Genito Urinary Cancer, Bladder Cancer, Kidney Cancer, Prostate Cancer
- Trial name
- Immune PDX (NCT03134027)
- Testing
- Bone marrow biopsy, Tumor biopsy
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Duke University
Prostate Cancer, Kidney Cancer
Patient Navigation Program to Improve Clinical Trial Enrollment in Cancer Patients
The goal of this clinical trial is to test the utility of patient navigation by comparing high intensity patient navigation to low intensity navigation approaches to improving cancer trial enrollment of patients treated in…
- Trial name
- NCT06138067
- Testing
- High intensity approach, Low intensity approach
- Where
- 2 sites in United States
- Volunteers
- 90 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Metastatic Renal Cell Carcinoma
A Phase II Study of AS1411 in Renal Cell Carcinoma
The aim of this study is to evaluate the efficacy of AS1411 in patients with Metastatic Renal Cell Carcinoma
- Trial name
- NCT00740441
- Testing
- AS1411
- Where
- 7 sites in United States
- Volunteers
- 30 people
- Sponsor
- Antisoma Research
Carcinoma, Renal Cell
Phase III Study of Sorafenib in Patients With Renal Cell Carcinoma (RCC)
A multicenter uncontrolled study of sorafenib in patients with unresectable and/or metastatic renal cell carcinoma (RCC) to assess the pharmacokinetic profile, safety and tolerability, and efficacy.
- Trial name
- NCT00586105
- Testing
- Sorafenib (Nexavar, BAY43-9006)
- Where
- 8 sites in China, Taiwan
- Volunteers
- 39 people
- Sponsor
- Bayer
Locally Advanced Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma
Optimizing Pazopanib Exposure in RCC Patients
Optimization of Pazopanib Exposition in Patients with Renal Cell Carcinoma by Therapeutic Drug Monitoring followed by Individual Dose Escalation.
- Trial name
- OPERA (NCT02089802)
- Testing
- Pazopanib
- Where
- 3 sites in Germany
- Volunteers
- 6 people
- Sponsor
- Interessenverband zur Qualitätssicherung der Arbeit niedergelassener Uro-Onkologen in Deutschland e.
Advanced Solid Tumor
Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor
This research study is studying an investigational combination of drugs as a possible treatment for advanced solid tumors: melanoma, ovarian, renal, or colorectal cancer. The drugs involved in this study are: Pembrolizumab AMG386
- Trial name
- NCT03239145
- Testing
- Pembrolizumab, Trebananib
- Where
- 2 sites in United States
- Volunteers
- 62 people
- Sponsor
- Dana-Farber Cancer Institute
Advanced Renal Cell Carcinoma
A Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell Carcinoma
This is an open-label, randomized, controlled, multi-national, multi-center, parallel-arm trial comparing tivozanib to sorafenib in subjects with advanced RCC.
- Trial name
- TIVO-1 (NCT01030783)
- Testing
- tivozanib (AV-951), Sorafenib
- Where
- 86 sites in United States, Argentina and 14 more
- Volunteers
- 517 people
- Sponsor
- AVEO Pharmaceuticals, Inc.
Renal Cell Carcinoma
RAD001 for Non-clear Cell Renal Cell Carcinoma (RCC)
To assess the efficacy and safety of RAD001 (everolimus) in non-clear cell renal cell carcinoma
- Trial name
- NCT00830895
- Testing
- RAD001
- Where
- South Korea
- Volunteers
- 49 people
- Sponsor
- Seoul National University Hospital
Kidney Cancer
Medroxyprogesterone or Interferon and/or Aldesleukin in Treating Patients With Metastatic Kidney Cancer
RATIONALE: Medroxyprogesterone may help shrink or slow the growth of kidney cancer. Interferon may interfere with the growth of tumor cells. Aldesleukin may stimulate white blood cells to kill tumor cells.
- Trial name
- NCT00416429
- Testing
- aldesleukin, recombinant interferon alpha-2a, medroxyprogesterone
- Volunteers
- 456 people
- Sponsor
- Centre Leon Berard
Clear Cell Renal Cell Carcinoma
Safety and Activity of G-202 in Patients With Clear Cell Renal Cell Carcinoma That Expresses PSMA
An open-label, single-arm, single-center Phase II study to evaluate the safety and activity of G-202 in patients with clear cell renal cell carcinoma that expresses PSMA
- Trial name
- NCT02607553
- Testing
- G-202
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- GenSpera, Inc.
Kidney Cancer, Head and Neck Cancer
177Lu-J591 Antibody in Patients With Nonprostate Metastatic Solid Tumors
The purpose of this study is to evaluate changes in tumor blood flow and disease response to the investigation agent, 177Lu-J591.
- Conditions
- Kidney Cancer, Head and Neck Cancer, Breast Cancer, Non-small Cell Lung Cancer
- Trial name
- NCT00967577
- Testing
- 177Lu-J591
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Weill Medical College of Cornell University
Clear Cell Renal Cell Carcinoma, Stage I Renal Cell Cancer
Pazopanib Hydrochloride Before Surgery in Treating Patients With Kidney Cancer
RATIONALE: Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving pazopanib hydrochloride before surgery may make the tumor smaller and reduce the amount of…
- Conditions
- Clear Cell Renal Cell Carcinoma, Stage I Renal Cell Cancer, Stage II Renal Cell Cancer, Stage III Renal Cell Cancer
- Trial name
- NCT01158521
- Testing
- pazopanib hydrochloride, therapeutic conventional surgery
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Case Comprehensive Cancer Center
Prostate Cancer (Adenocarcinoma), Bladder Cancer
Enhancing Readability of Lay Abstracts and Summaries for Medical Knowledge Using Generative Artificial Intelligence (BRIDGE AI 3)
This trial tests if AI can help make medical info clear and readable. Many patients struggle to find medical informations that easy to read and understand from verified medical sources.
- Conditions
- Prostate Cancer (Adenocarcinoma), Bladder Cancer, Kidney Cancers, Testis Cancer
- Trial name
- NCT07568444
- Testing
- Pub2Post
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- University of Southern California
Cancer, Breast Cancer
Liquid Biopsy Evaluation and Repository Development at Princess Margaret
The objective of this protocol is to develop an institution-wide liquid biopsy protocol that will establish a common process for collecting blood and corresponding archived tumor specimens for future research studies at the…
- Conditions
- Cancer, Breast Cancer, Lung Cancer, Colon Cancer
- Trial name
- LIBERATE (NCT03702309)
- Where
- Canada
- Volunteers
- 2,500 people, healthy volunteers welcome
- Sponsor
- University Health Network, Toronto
Renal Cell Carcinoma, Gastrointestinal Stromal Tumor
Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors
The purpose of this study is to determine if and how often an unexpected fast increase of disease and complaints shows after stopping the anti-angiogenetic therapy
- Trial name
- NCT00777504
- Testing
- usage oral angiogenesis inhibitor, stop oral angiogenesis inhibitor
- Where
- Netherlands
- Volunteers
- 30 people
- Sponsor
- Radboud University Medical Center